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a Heart, Trauma and Sepsis Research Laboratory, College of Medicine and Dentistry, James Cook University, Queensland 4811, Australia
b The Orthopaedic Research Institute of Queensland (ORIQL), Townsville, Queensland 4812, AustraliaThe germfree animal is free of all microorganisms, whereas the
disease-free animal may be described as one free of pathogens and
the clinical signs that they produce. … Suggested definitions are:
“animals free of commonly occurring pathogens and parasites,”
“specific pathogen-free,” “pathogen-free,” “Caesarean-derived,”
and “disease-free” animals.
[Henry L Foster (1959)]
In this commentary, we discuss the pros and cons of using specific
pathogen-free (SPF) animals in biomedical research, and present indi-
vidual cases where altering the gut microbiome has dramatically
changed the animal's basic physiology, immune/inflammatory func-
tions and susceptibility to infection and disease. We argue that SPF ma-
nipulation of the microbiome-host relationship has itself become a
confounding variable in biomedical research, which could have major
implications to human translation.1. Brief history
In the early 1960s, researchers were increasingly frustrated with the
presence of disease or infection as an unwanted variable in their exper-
iments [1]. A mandate led to new practices and guidelines for animal
housing and husbandry, including those from the National Institutes
of Health (NIH) in 1963. One breeding strategywas a ‘germ-free’ colony
that was free of ALL measurable microorganisms, including those typi-
cally found in the gut [1]. These animals were useful only if they
remained in their sterile ‘bubble’ because on transfer to a normal envi-
ronment they became ill or died. The next strategywas to breed healthy
animals free of selected pathogens, from germ-free stock or Caesarean
aseptic techniques, then expose the colony to an environment free of in-
fectious organisms (not all) that may otherwise interfere with research
goals and objectives [1].
Today, this latter SPF method of breeding is adopted by most com-
mercial and institutional animal husbandry facilities, with certification
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respiratory bacterial pathogens include Clostridium piliforme, Salmonella
spp, cilia-associated respiratory (CAR) Bacillus, Mycoplasma pulomonis,
and Citrobacter rodentium [3]. However, differences exist among breed-
ing facilities. For example, Charles River and Taconic Biosciences do not
exclude opportunistic organisms beta-hemolytic Streptococcus, Staphy-
lococcus aureus, Pseudomonas aeruginosa,Klebsiella spp. andHelicobacter
spp. [4], whereas they are excluded at Harvard Medical School [5], Cor-
nell University, and our own Australian Institute of Tropical Health and
Medicine. These SPF methods are in direct contrast to breeding conven-
tional healthy animals (sometimes called ‘dirty’ animals) in open cages
in a controlled, health-monitored and more natural environment of an-
tigenic exposures and indigenous gut flora.
2. Growing concerns
Concerns with SPF versus wild animals has a long history. In the
early-to-mid 1960s, microbiologist Rene Dubos and colleagues studied
germ-free, SPF and ‘normal’wild adult mice from the same genetic ori-
gin, and were among the first to show that changes in microbiota were
associated with differences in growth rate, efficiency in utilizing food,
social interactions, maternal care, resistance to infection and toxins, im-
mune function and stress [2]. Moreover, when germ-free or SPF mice
were housed with normal mice these changes reverted back to their
‘normal’ states. Dubos further reported that unlike ‘normal’ wild mice,
their SPF animals lacked facultatively anaerobic gram-negative bacteria,
such as Escherichia coli, in their gut microbiota [2].
In 1965, Dubos's colleague Russell Schaedler attempted to standard-
ize the practice by breedingmicewithmore conventional microbiota to
represent a natural state [6]. Schaedler colonized animals with two Lac-
tobacillus spp., an anaerobic Streptococcus spp. (group N), a strain of
Bacteroides, an Enterococcus spp., and a coliform strain, all of which
were isolated from Nelson Collins Swiss mice [6]. This microbial com-
munity became known as “Schaedler flora”, andwas supplied to animal
vendors for use as a base microbiota for newly derived germ-free ro-
dents. This pioneering work is rarely cited in the biomedical literature.
In 1978, Schaedler's PhD student, Roger Orcutt was asked by the Na-
tional Cancer Institute at NIH to develop a “refined microbiota” for
their contract suppliers (e.g., Charles River Laboratories, Taconic Biosci-
ences, Harlan Laboratories and Simonsen Laboratories) [7]. Today,
Orcutt's approach continues to be used in many SPF facilities aroundthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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barrier production [7].
Nearly 40 years later, a landmark study of Beura and colleagues
reported that ‘standard’ SPF adult mice have “immature” immune sys-
tems, andweremore prone to infection thanwildmice [8]. They further
showed that co-housing SPF animals with pet store mice reversed the
problem, and produced mice with immune systems closer to adult
humans [8]. Similarly, Rosshart and colleagues showed SPF-type mice
reconstituted with natural microbiota exhibited reduced inflammation
and increased survival following influenza virus infection, and displayed
improved resistance against colorectal tumorigenesis [9].
3. Translational gap
SPF gut microbiome heterogeneity may also contribute to the dis-
connect between animal studies showing promising drug development
and failure to translate to humans [10]. Problems with pre-clinical
modelling of human diseases was anticipated over 15 years ago by the
USA Food and Drug Administration (FDA) who recommended that:
“strengthening and rebuilding the disciplines of physiology, pharmacol-
ogy and clinical pharmacology, will be necessary to provide the capacity
to develop and evaluate new biomarkers and bridge across animal and
human studies” [11]. This FDA capacity-building, Critical Path Initiative
remains an ongoing challenge, and highlights another issue regarding
the use of SPF animals and the concept of reductionism in basic science
and its relevance to humans. The price we pay for using “Omics” technol-
ogies to drill deeper and deeper into life's hidden secrets is often at the ex-
pense of whole body systems analysis. Students of biomedicine need to
appreciate that probing the underlyingmechanisms of how drugs affect
cells or tissue culture is only one tiny step toward understanding how
they will behave inside a living organism. Differences in SPF colony
management and what pathogens are excluded (and included) are
rarely mentioned in discussions on why promising experiments in
small animal models often do not translate in human trials [12,13].
4. Recommendations
We are not recommending introducingwild or pet store animal into
a standard breeding colony at the risk of transmitting infectious micro-
organisms to resident animals or exposure of personnel to zoonotic
agents. We are suggesting, that if translation to humans is the end-
game, the best chance will be from a breeding colony that mimics a more
natural state in a controlled animal facility with routine microbiome profil-
ing, standard health screening and codified ethical practices. Different SPF,
germ-free and transgenic strains may be ideally suited for mechanistic
studies, with changes in the gut microbiome being used as a tool to in-
vestigate the pathogenesis of specific diseases. However, these animal
models may lack translation potential if the microbiome is far removed
froma natural state, and a conventionally-bred speciesmay be required.
To be fair, one could also argue that using a naturally bred colony of an-
imals could introduce wide variability in gut microbiota and confound
the research results. Finding the right balance is the key to translation.
In order to address the challenging questions of SPF definition and
heterogeneity for a particular animal species or research objective, we
propose the following recommendation which could accompany a
Data Availability Statement at the end of a scientific publication.Animal microbial/pathogen exclusion status: A list of pathogens
excluded in animals supporting the conclusions of this study are
available by contacting the author(s) and/or institutional data hub
(with an appropriate URL).
This proposal could bemandated by journal editors, and may represent
an important first step toward improving reproducibility and replicabil-
ity in animal models for translational biomedical research.
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